|
Learning how to conduct and design meaningful clinical trials
|
|
8
|
1480
|
September 3, 2024
|
|
Non-collapsibility of standardized rate
|
|
14
|
1284
|
August 31, 2024
|
|
Where are the exceptional responders?
|
|
2
|
881
|
July 31, 2024
|
|
Effect sizes for power and evidence for effectiveness
|
|
24
|
2669
|
July 24, 2024
|
|
Power and sample size planning with canonical correlation analysis
|
|
3
|
1257
|
July 23, 2024
|
|
Recovering utilities implicit in adaptive trial designs
|
|
5
|
1125
|
July 18, 2024
|
|
Health economic state-based transition models
|
|
3
|
1133
|
July 3, 2024
|
|
Progression in cancer trials
|
|
26
|
5808
|
June 25, 2024
|
|
Quality literature on the design and logistics of conducting a randomized controlled trial
|
|
4
|
3943
|
June 20, 2024
|
|
Power for a mixed ANOVA (2b x 2w)
|
|
2
|
936
|
June 8, 2024
|
|
Comparisons of Physicians and LLMs with Technical Replicates
|
|
1
|
1019
|
June 6, 2024
|
|
Method comparison study: Multiple experts vs AI
|
|
8
|
1980
|
May 21, 2024
|
|
Definition of Intention-to-Treat Set in Epic generated randomization
|
|
16
|
2647
|
May 4, 2024
|
|
Double Counting in Meta-Analysis
|
|
3
|
991
|
April 10, 2024
|
|
Sample size calculation for metabolomic profiles in a nested case-control study
|
|
0
|
1039
|
April 8, 2024
|
|
Immortal-time-bias vs. selection bias
|
|
2
|
1698
|
April 7, 2024
|
|
Run-in phase in RCTs
|
|
14
|
10454
|
April 1, 2024
|
|
Calculate incidence rate after adjustment
|
|
10
|
2445
|
March 19, 2024
|
|
Is Lithium Equivalent to Lecanemab in Slowing cognitive decline in Alzheimer's Disease?
|
|
0
|
1122
|
February 23, 2024
|
|
Review of Trial at the Center of the Firestorm Over Early Connection of Patients to Ventilators during the Pandemic
|
|
34
|
5643
|
February 16, 2024
|
|
RCT: protocol deviation and implications for analysis
|
|
6
|
1311
|
February 16, 2024
|
|
Handling missing continuous data due to death
|
|
7
|
1859
|
February 8, 2024
|
|
Sample Size calculation - "subgroup hypothesis", Guidance needed
|
|
2
|
1308
|
February 4, 2024
|
|
ITT analysis population - RCT
|
|
6
|
1764
|
February 3, 2024
|
|
Practicalities of using Markov Longitudinal Ordinal Models in Cardiovascular Outcome Trials
|
|
5
|
1338
|
January 25, 2024
|
|
Mixed vs Random Effects ICC
|
|
13
|
20671
|
January 23, 2024
|
|
Random vs. fixed effects meta-analysis
|
|
22
|
18641
|
January 20, 2024
|
|
Calculate event/total of an outcome that is reported as Hazard Ratio (95% CI, p-value)
|
|
1
|
768
|
January 10, 2024
|
|
Language for communicating frequentist results about treatment effects
|
|
200
|
124589
|
January 9, 2024
|
|
Substituting treatment arm with drug exposure (continuous variable) in RCT
|
|
10
|
1582
|
January 8, 2024
|